Kymera Therapeutics
KYMR
97 hedge funds and large institutions have $887M invested in Kymera Therapeutics in 2021 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 28 increasing their positions, 25 reducing their positions, and 6 closing their positions.
367% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 6
29% more funds holding
Funds holding: 75 → 97 (+22)
12% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 25
5.29% more ownership
Funds ownership: 45.66% → 50.95% (+5.3%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
29% less capital invested
Capital invested by funds: $1.25B → $887M (-$360M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$66.8M |
| 2 |
State Street
Boston,
Massachusetts
|
+$46.7M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$32.6M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$23.9M |
| 5 |
Morgan Stanley
New York
|
+$20.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$61.5M |
| 2 |
CCM
CAAS Capital Management
New York
|
-$10.5M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$10.5M |
| 4 |
TOCUITCONY
Trustees of Columbia University in the City of New York
New York
|
-$9.04M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
-$7.06M |
KYMR Hedge Fund Activity: Q1 2021 in Review
97 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Kymera Therapeutics (KYMR) for Q1 2021, worth a combined $887M — down 29% from $1.25B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new KYMR positions and 6 closed out — a net gain of 22 holders — while 28 added to existing stakes and 25 trimmed.
The largest buyer was Vanguard Group, adding an estimated $66.8M. The largest seller was Wellington Management Group, cutting an estimated $61.5M.
- 97 institutional investors held Kymera Therapeutics (KYMR) as of Q1 2021, up from 75 in Q4 2020.
- Funds reported $887M of Kymera Therapeutics stock for Q1 2021, down 29% quarter-over-quarter.
- 28 funds opened new Kymera Therapeutics positions in Q1 2021 and 6 closed out, a net change of +22 holders.
- The largest Kymera Therapeutics buyer in Q1 2021 was Vanguard Group, an estimated $66.8M added.
- The largest Kymera Therapeutics seller in Q1 2021 was Wellington Management Group, an estimated $61.5M sold.
Based on aggregated 13F filings for Q1 2021.